These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35322390)

  • 1. Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study.
    Currie GR; Pham T; Twilt M; IJzerman MJ; Hull PM; Kip MMA; Benseler SM; Hazlewood GS; Yeung RSM; Wulffraat NM; Swart JF; Vastert SJ; Marshall DA
    Patient; 2022 Sep; 15(5):599-609. PubMed ID: 35322390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey.
    Currie GR; Groothuis-Oudshoorn CGM; Twilt M; Kip MMA; IJzerman MJ; Benseler SM; Swart JF; Vastert SJ; Wulffraat NM; Yeung R; Marshall DA
    Clin Rheumatol; 2023 Aug; 42(8):2173-2180. PubMed ID: 37202606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
    van Til JA; Kip MMA; Schatorjé EJH; Currie G; Twilt M; Benseler SM; Swart JF; Vastert SJ; Wulffraat N; Yeung RSM; Groothuis-Oudshoorn CGMK; Warta S; Marshall DA; IJzerman MJ;
    Pediatr Rheumatol Online J; 2023 Jul; 21(1):69. PubMed ID: 37434157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives.
    Chan SJ; Stamp LK; Liebergreen N; Ndukwe H; Marra C; Treharne GJ
    Patient; 2020 Apr; 13(2):225-234. PubMed ID: 31802391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "I'd like more options!": Interviews to explore young people and family decision-making needs for pain management in juvenile idiopathic arthritis.
    Toupin-April K; Gaboury I; Proulx L; Huber AM; Duffy CM; Morgan EM; Li LC; Stringer E; Connelly M; Weiss JE; Gibbon M; Sachs H; Sivakumar A; Sirois A; Sirotich E; Trehan N; Abrahams N; Cohen JS; Cavallo S; Hindi TE; Ragusa M; Légaré F; Brinkman WB; Fortin PR; Décary S; Lee R; Gmuca S; Paterson G; Tugwell P; Stinson JN
    Pediatr Rheumatol Online J; 2023 Jul; 21(1):74. PubMed ID: 37491246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient and rheumatologist perspectives on tapering DMARDs in rheumatoid arthritis: a qualitative study.
    Hazlewood GS; Loyola-Sanchez A; Bykerk V; Hull PM; Marshall D; Pham T; Barber CEH; Barnabe C; Sirois A; Pope J; Schieir O; Richards D; Proulx L; Bartlett SJ
    Rheumatology (Oxford); 2022 Feb; 61(2):606-616. PubMed ID: 33878168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey.
    Shenoi S; Nanda K; Schulert GS; Bohnsack JF; Cooper AM; Edghill B; Gillispie-Taylor MC; Goldberg B; Halyabar O; Mason TG; Ronis T; Schneider R; Vehe RK; Onel K;
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):48. PubMed ID: 31331351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance.
    Horton DB; Onel KB; Beukelman T; Ringold S
    J Rheumatol; 2017 Mar; 44(3):352-360. PubMed ID: 28148696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding treatment decision making in juvenile idiopathic arthritis: a qualitative assessment.
    Lipstein EA; Brinkman WB; Sage J; Lannon CM; Morgan Dewitt E
    Pediatr Rheumatol Online J; 2013 Sep; 11(1):34. PubMed ID: 24079577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decision Aid-Led Tapering of Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: A Qualitative Study.
    Lee J; Barber C; Jung M; Kaminska E; Bansback N; Richards D; Proulx L; Rebutoc A; Hazlewood GS
    J Rheumatol; 2024 Aug; ():. PubMed ID: 39147416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment and treatment of Down syndrome-associated arthritis: a survey of pediatric rheumatologists.
    Nicek A; Talib N; Lovell D; Smith C; Becker ML; Jones JT
    Pediatr Rheumatol Online J; 2020 Jul; 18(1):57. PubMed ID: 32660497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making.
    Bolge SC; Goren A; Brown D; Ginsberg S; Allen I
    Patient Prefer Adherence; 2016; 10():1079-90. PubMed ID: 27390518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis.
    Kearsley-Fleet L; Baildam E; Beresford MW; Douglas S; Foster HE; Southwood TR; Hyrich KL; Ciurtin C
    Rheumatology (Oxford); 2023 May; 62(5):1926-1935. PubMed ID: 36104094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of juvenile idiopathic arthritis in early adulthood with biologics: transition from pediatric to adult care].
    Niewerth M; Minden K; Klotsche J; Horneff G
    Z Rheumatol; 2014 Aug; 73(6):532-40. PubMed ID: 25096586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transitions from pediatric to adult rheumatology care for juvenile idiopathic arthritis: a patient led qualitative study.
    Currie GR; Harris M; McClinton L; Trehan N; Van Dusen A; Shariff M; Kuzmyn T; Marshall DA
    BMC Rheumatol; 2022 Nov; 6(1):85. PubMed ID: 36376987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.
    Halyabar O; Mehta J; Ringold S; Rumsey DG; Horton DB
    Paediatr Drugs; 2019 Dec; 21(6):469-492. PubMed ID: 31673960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What matters most for patients, parents, and clinicians in the course of juvenile idiopathic arthritis? A qualitative study.
    Guzman J; Gómez-Ramírez O; Jurencak R; Shiff NJ; Berard RA; Duffy CM; Oen K; Petty RE; Benseler SM; Brant R; Tucker LB
    J Rheumatol; 2014 Nov; 41(11):2260-9. PubMed ID: 25225279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
    Davies R; Gaynor D; Hyrich KL; Pain CE
    Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
    Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
    Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.